A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
- Registration Number
- NCT04374253
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE) part.
- Detailed Description
Participants who were in the active arm in the double blind part and those who have completed OLE part in the parent study, will continue receive open-label gantenerumab 510 mg sub-cutaneously (SC) every 2 weeks (Q2W). Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme as in the parent study before ...
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1382
- Completed Study WN29922 or WN39658, either its double-blind part or OLE part, and did not discontinue study drug early
- The participant should be capable of completing assessments either alone or with the help of the caregiver
- Availability of a person (referred to as the "caregiver")
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception methods with a failure rate of <1% per year (bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the treatment period and for at least 16 weeks after the final dose of gantenerumab
- Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug
- Pregnant or breastfeeding, or intending to become pregnant during the study or within at least 16 weeks after the final dose of study drug
- Prematurely discontinued from Study WN29922 or WN39658
- Any medical condition that may jeopardize the participant's safety if he or she continues to receive study treatment
- Received any investigational treatment other than gantenerumab during or since completion of Study WN29922 or WN39658, either its double-blind or OLE part
- Evidence of disseminated leptomeningeal hemosiderosis
- Evidence of intracerebral macrohemorrhage
- Use of prohibited medication
- Evidence of ARIA-E on the last MRI scan report in Study WN29922 or WN39658, either its double-blind or OLE part
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Group 1 Gantenerumab Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 116 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1). Group 2 Gantenerumab Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.
- Primary Outcome Measures
Name Time Method Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI From Baseline (OLE Day 1) up to 14 weeks after the last dose (up to 134 weeks) ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal ...
Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by MRI From Baseline (OLE Day 1) up to 14 weeks after the last dose (up to 134 weeks) ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces. The first dosing visit in the OLE (first dosing in current stud...
Number of Participants With Injection-Site Reactions (ISRs) From Baseline (OLE Day 1) up to 14 weeks after the last dose (up to 134 weeks) An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product, regardless of casual attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be ...
Number of Participants Who Discontinued the Study Due an AE From Baseline (OLE Day 1) up to 14 weeks after the last dose (up to 134 weeks) An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of casual attribution. The first dosing visit in the OLE (first dosing in current study or first dosing in the OLE period of the parent GRADUATE studies) was considered as baseline (OLE Day 1).
Number of Participants With at Least One Adverse Event of Special Interest (AESI) From Baseline (OLE Day 1) up to 14 weeks after the last dose (up to 134 weeks) An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of casual attribution. AEs that were considered to be of special interest for this study included cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin o...
Number of Participants With at Least One Adverse Event (AE) and Serious Adverse Event (SAE) From Baseline (OLE Day 1) up to 14 weeks after the last dose (up to 134 weeks) An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of casual attribution. A SAE is any AE that is fatal, life threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in a neonate...
Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) Score From Baseline (OLE Day 1) up to 14 weeks after the last dose (up to 134 weeks) C-SSRS= assesses lifetime suicidality of participant (at baseline) \& any new instances of suicidality (since last visit). Structured interview prompts recollection of suicidal ideation (intensity of ideation, behavior, \& attempts with actual/potential lethality). Categories have yes/no responses, include Wish to be Dead; Non-specific Active Suicidal Though...
- Secondary Outcome Measures
Name Time Method Change From Baseline Over Time in Clinical Dementia Rating - Global Score (CDR-GS) Baseline (OLE Day 1), Weeks 24, 36, 52, 76 and 104 CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=normal, 0.5=very mild dementia, 1=mild dementia, 2=moderate dementia, and 3= ...
Change From Baseline Over Time in Mini-Mental State Examination (MMSE) Score Baseline (OLE Day 1), Weeks 24, 36, 52, 76 and 104 MMSE is a rater-administered performance-based outcome (PerfO) that includes a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target six areas: orientation, registration, attention, short-term recall, language, and constructional praxis/visuospatial abilities. T...
Change From Baseline Over Time in Alzheimer Disease Assessment Scale-Cognition, Subscale 13 (ADAS-Cog13) Score Baseline (OLE Day 1), Weeks 24, 36, 52, 76 and 104 The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 in addition to delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score...
Change From Baseline Over Time in Verbal Fluency Task Score Baseline (OLE Day 1), Weeks 24, 36, 52, 76 and 104 VFT is a rater administered PerfO that measures speed and flexibility of verbal thought with a total score that ranges from 0-99 (lower scores indicating lower performance). A positive change from baseline indicates improvement. The first dosing visit in the OLE (first dosing in current study or first dosing in the OLE period of the parent GRADUATE studies) ...
Change From Baseline Over Time in Clinical Dementia Rating (CDR) - Sum of Boxes (SB) Baseline (OLE Day 1), Weeks 24, 36, 52, 76 and 104 CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=no impairment, 0.5=questionable impairment, and 1, 2, and 3=mild, moderate, a...
Change From Baseline Over Time in Alzheimer Disease Assessment Scale-Cognition, Subscale 11 (ADAS-Cog11) Score Baseline (OLE Day 1), Weeks 24, 36, 52, 76 and 104 ADAS-Cog11 was designed to measure cognitive symptom change in participants with Alzheimer's Disease (AD) and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12),...
Change From Baseline Over Time in Coding (Digit Symbol Substitution Test [DSST]) Subset Baseline (OLE Day 1), Weeks 24, 36, 52, 76 and 104 Coding, also called DSST is a rater administered PerfO that measures speed of processing and associative memory with a total score that ranges from 0-135 (lower scores indicating lower performance). The DSST was adapted from the Wechsler Adult Intelligence Scale. The 120-second version of the test was used in this study. Positive change from baseline indicat...
Number of Participants With Anti-drug Antibody (ADA) to Gantenerumab From Baseline (OLE Day 1) up to 14 weeks after the last dose (up to 134 weeks) The number of participants with positive results for ADA against gantenerumab at any of the post-baseline assessment time-points were reported. Evaluable participant during OLE was participant with an ADA assay result from at least one sample during OLE. Treatment Emergent ADA = A participant with a negative or missing baseline ADA result(s) and at least one...
Change in Functional Activities Questionnaire (FAQ) Score Baseline (OLE Day 1), Weeks 24, 36, 52, 76 and 104 FAQ is a rater-administered observer-reported outcome (ObsRO) (informant-based measure) that measures a participant's functional ability to perform complex higher-order activities. The observer provides performance ratings of the target person on ten complex higher-order activities. Total score that ranges from 0-30, with higher scores reflecting greater fun...
Change in Alzheimer Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL) Score Baseline (OLE Day 1), Weeks 24, 36, 52, 76 and 104 ADCS-ADL is a 23-item rater-administered, ObsRO that captures a participant's ability to perform basic activities of daily living (e.g., eating and toileting) and more complex ADL or instrumental activities of daily living (iADL, e.g., using the telephone, managing finances, preparing a meal). Total score ranges from 0-78, with higher scores reflecting bette...
Trial Locations
- Locations (268)
Research Center for Clinical Studies, Inc.
🇺🇸Norwalk, Connecticut, United States
Brain Matters Research, Inc.
🇺🇸Delray Beach, Florida, United States
Infinity Clinical Research, LLC
🇺🇸Sunrise, Florida, United States
Banner Sun Health Research Insitute
🇺🇸Sun City, Arizona, United States
Intercoastal Medical Group
🇺🇸Sarasota, Florida, United States
Renstar Medical Research
🇺🇸Ocala, Florida, United States
Kerwin Medical Center
🇺🇸Dallas, Texas, United States
Baycrest Health Sciences
🇨🇦Toronto, Ontario, Canada
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, RS, Brazil
Alzheimer?s Research and Treatment Center
🇺🇸Wellington, Florida, United States
Biomedica Research Group
🇨🇱Santiago, Chile
Neurological Associates of Long Island, PC
🇺🇸Lake Success, New York, United States
The Cognitive and Research Center of New Jersey
🇺🇸Springfield, New Jersey, United States
Instituto Kremer
🇦🇷Córdoba, Argentina
AZ Sint Blasius (Dendermonde)
🇧🇪Dendermonde, Belgium
University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
Hospital das Clinicas - FMUSP_X; Neurologia
🇧🇷Sao Paulo, SP, Brazil
Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie
🇩🇪München, Germany
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
CEN Centro Especializado en Neurociencias
🇦🇷Cordoba, Argentina
Fundación Scherbovsky; General Department
🇦🇷Mendoza, Argentina
UZ Gent
🇧🇪Gent, Belgium
St Vincent's Hospital Sydney; Neurology
🇦🇺Darlinghurst, New South Wales, Australia
Alpha Recherche Clinique
🇨🇦Quebec, Canada
Especialidades Medicas LYS
🇨🇱Santiago, Chile
Universitätsklinikum Köln; Klinik und Poliklinik für Psychiatrie und Psychotherapie
🇩🇪Köln, Germany
Forschungszentrum Ruhr
🇩🇪Witten, Germany
Devonshire Clinical Research
🇨🇦Woodstock, Ontario, Canada
Terveystalo Ruoholahti
🇫🇮Helsinki, Finland
mMED Maciej Czarnecki
🇵🇱Warszawa, Poland
CHU Strasbourg Hôpital Hautepierre
🇫🇷Strasbourg, France
PANAKEIA - Arzneimittelforschung Leipzig GmbH
🇩🇪Leipzig, Germany
Universitätsmedizin derJohannes Gutenberg-Universität Mainz;Klinik für Psychiatrie und Psychotherapi
🇩🇪Mainz, Germany
Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica
🇮🇹Roma, Lazio, Italy
Umberto I Policlinico di Roma-Università di Roma La Sapienza
🇮🇹Roma, Lazio, Italy
Ospedale San Giovanni Calibita Fatebenefratell;Neurologia
🇮🇹Roma, Lazio, Italy
Ambulates Gesundheitszentrum der Charité GmbH; MVZ Neurologie Campus Benjamin Franklin
🇩🇪Berlin, Germany
Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica ? Dipartimento di Neuroscienze
🇮🇹Modena, Emilia-Romagna, Italy
Hopital des Charpennes
🇫🇷Villeurbanne, France
Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie
🇩🇪Münster, Germany
Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz
🇩🇪Westerstede, Germany
ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic
🇩🇪Berlin, Germany
IRCCS ?Centro S. Giovanni di Dio? Fatebenefratelli -UO Alzheimer
🇮🇹Brescia, Lombardia, Italy
Semmelweis University; Department of Neurology
🇭🇺Budapest, Hungary
National Center for Geriatrics and Gerontology
🇯🇵Aichi, Japan
Rakuwakai Otowa Hospital
🇯🇵Kyoto, Japan
Rijikai Medical Corporation Katayama Medical Clinic
🇯🇵Okayama, Japan
Universitätsklinikum Rostock Zentrum für Nervenheilkunde
🇩🇪Rostock, Germany
AO Città della Salute e della Scienza Osp.S.Giov.Battista Molinette; SC Geriatria
🇮🇹Torino, Piemonte, Italy
Uji Takeda Hospital
🇯🇵Kyoto, Japan
Nozomi Memory Clinic
🇯🇵Tokyo, Japan
AVIX Investigación Clínica S.C
🇲🇽Monterrey, Nuevo LEON, Mexico
Brain Research Center B.V
🇳🇱Amsterdam, Netherlands
Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion
🇵🇪Bellavista, Peru
Hospital da Senhora da Oliveira-Guimarães; Serviço de Neurologia
🇵🇹Guimarães, Portugal
University ?linic of headaches
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
Tokyo Bay Advanced Medical and Makuhari Clinic
🇯🇵Chiba, Japan
Okayama Kyokuto Hospital
🇯🇵Okayama, Japan
Kishiwada Tokushukai Hospital
🇯🇵Osaka, Japan
Clinica Universitaria de Navarra
🇪🇸Pamplona, Navarra, Spain
National Hospital Organization Hizen Psychiatric Medical Center
🇯🇵Saga, Japan
National Center of Neurology and Psychiatry
🇯🇵Tokyo, Japan
Fundación ACE; Servicio de Neurología
🇪🇸Barcelona, Spain
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
IRCCS Ospedale San Raffaele; Centro Disturbi della Memoria
🇮🇹Milano, Lombardia, Italy
ASST DI MONZA; Neurologia
🇮🇹Monza, Lombardia, Italy
Dipartimento delle Patologie Emergenti; Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
🇮🇹Palermo, Sicilia, Italy
Kagawa Prefectural Central Hospital
🇯🇵Kagawa, Japan
Nagoya Ekisaikai Hospital
🇯🇵Aichi, Japan
Matsui Dietary and Dementia Clinic
🇯🇵Hyogo, Japan
MI Clinic
🇯🇵Osaka, Japan
Shizuoka City Shimizu Hospital
🇯🇵Shizuoka, Japan
Tokushima Hospital
🇯🇵Tokushima, Japan
Tokyo Medical University Hospital
🇯🇵Tokyo, Japan
Dong-A University Hospital
🇰🇷Busan, Korea, Republic of
NZOZ WCA
🇵🇱Wroc?aw, Poland
Re:Cognition Health London
🇬🇧London, United Kingdom
Hospital Ramon y Cajal; Servicio de Neurologia
🇪🇸Madrid, Spain
Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría
🇪🇸Salamanca, Spain
Hospital General Universitario de Albacete; Servicio de Neurología
🇪🇸Albacete, Spain
The Rice Centre; Royal United Hospital
🇬🇧Bath, United Kingdom
Ninewells Hospital
🇬🇧Dundee, United Kingdom
University Southampton NHS Foundation Trust; Wessex Neurologica Centre
🇬🇧Southampton, United Kingdom
CAE OROITU; Servicio de Neurología
🇪🇸Getxo, Vizcaya, Spain
Hospital Clinic i Provincial; Servicio de Neurologia
🇪🇸Barcelona, Spain
Surrey and Borders NHS Foundation Trust; Research and Development Department
🇬🇧Chertsey, United Kingdom
Policlínica Guipuzcoa; Servicio de Neurología
🇪🇸Donostia-san Sebastian, Guipuzcoa, Spain
Hospital Vall d'Hebron; Servicio de Neurología
🇪🇸Barcelona, Spain
Re:Cognition Health Birmingham
🇬🇧Birmingham, United Kingdom
The Fritchie Centre, Charlton Lane Centre, Charlon Lane, Leckhampton; The Fritchie Centre
🇬🇧Cheltenham, United Kingdom
Hospital del Mar; Servicio de Neurologia
🇪🇸Barcelona, Spain
Universitario de La Princesa; Servicio de Neurología
🇪🇸Madrid, Spain
Hospital Universitario de Santa Maria; Servicio de Neurología
🇪🇸Lleida, Lerida, Spain
Campus for Ageing and Vitality
🇬🇧Newcastle, United Kingdom
Hospital Universitario 12 de Octubre; Servicio de Neurologia
🇪🇸Madrid, Spain
Cleveland Clinic; Cleveland Lou Ruvo Center for Brain Health ? Neurological Institute
🇺🇸Cleveland, Ohio, United States
The University of Texas Health Science Center at Houston
🇺🇸Houston, Texas, United States
Brigham and Womens Hospital; Center for Alzheimer Research & Treatment
🇺🇸Boston, Massachusetts, United States
Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine
🇺🇸Houston, Texas, United States
UW Wisconsin-Madison
🇺🇸Madison, Wisconsin, United States
The Queen Elizabeth Hospital; Neurology
🇦🇺Woodville, South Australia, Australia
Central Coast Neurosciences Research
🇦🇺Erina, New South Wales, Australia
Southern Neurology
🇦🇺Kogarah, New South Wales, Australia
Instituto de Neurologia de Curitiba
🇧🇷Curitiba, PR, Brazil
Parkwood Hospital; Geriatric Medicine
🇨🇦London, Ontario, Canada
Aarhus Universitetshospital; Neurologisk Afd. F, Demensklinikken
🇩🇰Aarhus N, Denmark
CHU Amiens Hopital Sud; Neurologie
🇫🇷Amiens Cedex1, France
Gerontopole; Centre de Recherche clinique
🇫🇷Toulouse, France
Kobe University Hospital
🇯🇵Hyogo, Japan
Juntendo University Urayasu Hospital
🇯🇵Chiba, Japan
Yachiyo Hospital
🇯🇵Aichi, Japan
Medical Corporation Hakuyokai Kashiwado Hospital
🇯🇵Chiba, Japan
Inage Neurology and Memory Clinic
🇯🇵Chiba, Japan
National Hospital Organization Hiroshima-Nishi Medical Center
🇯🇵Hiroshima, Japan
Southern Tohoku Medical Clinic
🇯🇵Fukushima, Japan
Hyogo Prefectural HarimaHimeji General Medical Center
🇯🇵Hyogo, Japan
Tsukazaki Hospital
🇯🇵Hyogo, Japan
Hospital Universitario Dr Jose Eleuterio Gonzalez UANL; Depto.de NeurologíaPta.BajaConsulta
🇲🇽Monterrey, Nuevo LEON, Mexico
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Clinica Internacional; Unidad De Investigacion
🇵🇪Lima, Peru
Vertebronevrologiya LLC
🇷🇺Kazan, Tatarstan, Russian Federation
City Polyclinic No. 2 of the Department of Healthcare of the City of Moscow
🇷🇺Moskva, Moskovskaja Oblast, Russian Federation
Clinica Universitaria de Navarra; Servicio de Neurología
🇪🇸Pamplona, Navarra, Spain
Hospital Ruber Internacional; Servicio de Neurología
🇪🇸Madrid, Spain
Complejo Asistencial de Zamora; Servicio Psiquiatria
🇪🇸Zamora, Spain
Hospital Universitario Dr. Peset; Servicio de Neurologia
🇪🇸Valencia, Spain
Skånes Universitetssjukhus Malmö, Minneskliniken
🇸🇪Malmö, Sweden
Queen Elizabeth University Hospital - PPDS
🇬🇧Glasgow, United Kingdom
Beijing Tian Tan Hospital,Capital Medical University
🇨🇳Beijing City, China
Hospital Quiron de Madrid; Servicio de Neurologia
🇪🇸Pozuelo de Alarcon, Madrid, Spain
Australian Alzheimer's Research Foundation
🇦🇺Nedlands, Western Australia, Australia
Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC
🇲🇽Culiacán, Sinaloa, Mexico
HM Universitario Puerta del Sur CINAC (C.Integ.Neuroc);; Servicio de Psiquiatría
🇪🇸Móstoles, Madrid, Spain
Via Christi Research
🇺🇸Wichita, Kansas, United States
IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA
🇮🇹Pozzilli, Molise, Italy
Fullerton Neurology and Headache Center
🇺🇸Fullerton, California, United States
Neurology Center of North Orange County
🇺🇸Fullerton, California, United States
Irvine Center for Clinical Research
🇺🇸Irvine, California, United States
Syrentis Clinical Research
🇺🇸Santa Ana, California, United States
Desert Valley Research
🇺🇸Redlands, California, United States
California Neuroscience Research Medical Group, Inc
🇺🇸Sherman Oaks, California, United States
Southern California Research LLC
🇺🇸Simi Valley, California, United States
Emory University
🇺🇸Atlanta, Georgia, United States
Center for Advanced Research & Education
🇺🇸Gainesville, Georgia, United States
Fort Wayne Neurological Center
🇺🇸Fort Wayne, Indiana, United States
Southern Illinois University, School of Medicine
🇺🇸Springfield, Illinois, United States
American Health Network Institute, LLC
🇺🇸Avon, Indiana, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Missouri Memory Center
🇺🇸Bolivar, Missouri, United States
Columbia University Medical Center
🇺🇸New York, New York, United States
AD-CARE, University of Rochester Medical Center
🇺🇸Rochester, New York, United States
Richmond Behavioral Associates
🇺🇸Staten Island, New York, United States
Behavioral Health Research
🇺🇸Charlotte, North Carolina, United States
Raleigh Neurology Associates
🇺🇸Raleigh, North Carolina, United States
Alzheimer's Memory Center
🇺🇸Matthews, North Carolina, United States
Ohio State University; College of Medicine
🇺🇸Columbus, Ohio, United States
Abington Neurological Associates
🇺🇸Abington, Pennsylvania, United States
Neurology Consultants of Dallas; Research Department
🇺🇸Dallas, Texas, United States
The Clinical Trial Center, LLC
🇺🇸Jenkintown, Pennsylvania, United States
Sentara Neurology Specialists
🇺🇸Norfolk, Virginia, United States
University of Virginia
🇺🇸Charlottesville, Virginia, United States
Rigshospitalet, Hukommelsesklinikken
🇩🇰København Ø, Denmark
Svendborg Sygehus; Neurologisk afdeling N, Demensklinik Fyn
🇩🇰Svendborg, Denmark
Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust
🇬🇧Sheffield, United Kingdom
Allied Biomedical Research Institute, Inc
🇺🇸Miami, Florida, United States
Cleveland Clinic Lou Ruvo; Center for Brain Research
🇺🇸Las Vegas, Nevada, United States
Summit Research Network Inc.
🇺🇸Portland, Oregon, United States
Wasatch Clinical Research, LLC
🇺🇸Salt Lake City, Utah, United States
Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry
🇸🇪Mölndal, Sweden
KAROLINSKA UNI HOSPITAL, HUDDINGE; Mottagning Kognitiv Forskning, M54
🇸🇪Stockholm, Sweden
University of Nebraska Medical Center; Dept of Neurological Sciences
🇺🇸Omaha, Nebraska, United States
Hospital Virgen del Rocío; Servicio de Neurología
🇪🇸Sevilla, Spain
Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia
🇪🇸Barcelona, Spain
Hospital Universitario Reina Sofia; Servicio de Neurologia
🇪🇸Cordoba, Spain
Hospital Universitario la Fe; Servicio de Neurologia
🇪🇸Valencia, Spain
Servicio de Neurología Hospital Viamed Montecanal.
🇪🇸Zaragoza, Spain
Optimus U Corp
🇺🇸Miami, Florida, United States
Jessa Zkh (Campus Virga Jesse)
🇧🇪Hasselt, Belgium
Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia
🇧🇷Curitiba, PR, Brazil
Center for Diagnosis and Research on Alzheimer's disease
🇨🇦Greenfield Park, Quebec, Canada
Axiom Clinical Research of Florida
🇺🇸Tampa, Florida, United States
St George?s Hospital
🇬🇧London, United Kingdom
Hospital Victoria Eugenia; Servico Neurología
🇪🇸Sevilla, Spain
Sutter Medical Group, Neurology
🇺🇸Sacramento, California, United States
Yale University School Of Medicine
🇺🇸New Haven, Connecticut, United States
Wake Forest University
🇺🇸Winston-Salem, North Carolina, United States
JEM Research LLC
🇺🇸Atlantis, Florida, United States
Seoul St Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Konkuk University Medical Center
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Ewha Womans University Hospital (Seoul)
🇰🇷Seoul, Korea, Republic of
Health Initiatives Research, PLLC
🇺🇸Fayetteville, Arkansas, United States
Bradenton Research Center
🇺🇸Bradenton, Florida, United States
Hôpital Lariboisière
🇫🇷Paris, France
Advanced Memory Research Institute of NJ
🇺🇸Toms River, New Jersey, United States
Banner Alzheimer?s Institute
🇺🇸Phoenix, Arizona, United States
Psicomed Estudios Médicos
🇨🇱Antofagasta, Chile
Groupement Hospitalier Est - Hôpital Neurologique; Neurologie A (U502)
🇫🇷Bron cedex, France
Fukuoka University Hospital
🇯🇵Fukuoka, Japan
Georgetown University Medical Center
🇺🇸Washington, District of Columbia, United States
ClinCloud, LLC
🇺🇸Maitland, Florida, United States
Accel Research Sites - CRU Tampa
🇺🇸Bradenton, Florida, United States
Universidad Maimonides
🇦🇷Caba, Argentina
Clinica Clinilive ltda
🇧🇷Maringa, PR, Brazil
Itä-Suomen yliopisto, Kuopion kampus
🇫🇮Kuopio, Finland
Universitätsklinikum Ulm; Klinik für Neurologie
🇩🇪Ulm, Germany
Medical corporation Ichiekai Itsuki Hospital
🇯🇵Tokushima, Japan
Tokyo Medical and Dental University Hospital
🇯🇵Tokyo, Japan
Myongji Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
The Medical Arts Health Research Group - West Vancouver
🇨🇦Vancouver, British Columbia, Canada
Hospital Italiano
🇦🇷Caba, Argentina
Instituto Geriatrico Nuestra Señora de las Nieves
🇦🇷Capital Federal, Argentina
Instituto de Neurociencias San Agustín S.A.
🇦🇷La Plata, Argentina
CHU de la Timone - Hopital d Adultes; Service de Neurologie
🇫🇷Marseille, France
Shonan Kamakura General Hospital
🇯🇵Kanagawa, Japan
Barrow Neurological Institute
🇺🇸Phoenix, Arizona, United States
Vilnius University Hospital Santariskiu Clinics; Neurology
🇱🇹Vilnius, Lithuania
O?rodek Badawczo-Naukowo-Dydaktyczny Chorób Ot?piennych w ?cinawie
🇵🇱?cinawa, Poland
Podlaskie Centrum Psychogeriatrii
🇵🇱Bia?ystok, Poland
Pratia S.A.
🇵🇱Warszawa, Poland
HUC; Servico de Neurologia
🇵🇹Coimbra, Portugal
Hôpital Avicenne; Centre de Recherche Clinique
🇫🇷Bobigny Cedex, France
NHO Shizuoka Institute of Epilepsy and Neurological Disorders
🇯🇵Shizuoka, Japan
Senior Sp. Z O.O. Poradnia Psychogeriatryczna
🇵🇱Sopot, Poland
Hospital Geral de Santo Antonio; Servico de Neurologia
🇵🇹Porto, Portugal
Chang Gung Memorial Foundation - Linkou - Neurology
🇨🇳Taoyuan, Taiwan
Hospital Virgen del Puerto. Servicio de Neurología
🇪🇸Plasencia, Caceres, Spain
National Taiwan University Hospital; Neurology
🇨🇳Taipei, Taiwan
CHU Poitiers - Hopital La Miletrie
🇫🇷Poitiers, France
Jichiidai Station Brain Clinic
🇯🇵Tochigi, Japan
P-One Clinic
🇯🇵Tokyo, Japan
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Mexico Centre for Clinical Research
🇲🇽Ciudad de México, Mexico CITY (federal District), Mexico
State autonomous institution of healthcare Inter-regional clinical and diagnostic center
🇷🇺Kazan, Tatarstan, Russian Federation
MHI City Clinical Hospital #2 named after V.I. Razumovsky; Psychiatric
🇷🇺Saratov, Russian Federation
Nebbiolo Center for Clinical Trials
🇷🇺Tomsk, Russian Federation
Hospital Universitari de Bellvitge; Servicio de Neurologia
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
Changhua Christian Hospital; Neurology
🇨🇳Changhua County, Taiwan
Kaohsiung Medical University Hospital; Neurology
🇨🇳Kaohsiung, Taiwan
Yamagata Tokusyukai Hospital
🇯🇵Yamagata, Japan
NZOZ Vitamed
🇵🇱Bydgoszcz, Poland
City Clin Hosp n.a. S.P.Botkin
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
Hospital General Universitario de Elche; Servicio de Neurología
🇪🇸Elche, Alicante, Spain
China Medical University Hospital; Neurology
🇨🇳North Dist., Taiwan
Ondokuz Mayis Univ. Med. Fac.; Neurology
🇹🇷Samsun, Turkey
Hospital General De Catalunya; Servicio de Neurologia
🇪🇸Sant Cugat del Valles, Barcelona, Spain
Hospital Mutua De Terrasa; Servicio de Neurologia
🇪🇸Terrassa, Barcelona, Spain
Inha University Hospital
🇰🇷Incheon, Korea, Republic of
Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia
🇵🇪Lima, Peru
NEURO-CARE Sp. z o.o. Sp. Komandytowa
🇵🇱Katowice, Poland
KO-MED Centra Kliniczne Lublin II
🇵🇱Lublin, Poland
Neurologiczny NZOZ Centrum Leczenia SM; Osrodek Badan Klinicznych
🇵🇱Plewiska, Poland
Hospital de Braga; Servico de Neurologia
🇵🇹Braga, Portugal
Santa Cruz Behavioral PSC
🇵🇷Bayamon, Puerto Rico
FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency
🇷🇺Krasnoyarsk, Krasnojarsk, Russian Federation
Chang Gung Memorial Foundation - Kaohsiung - Neurology
🇨🇳Niaosong Dist., Taiwan
Hanyang University Seoul Hospital
🇰🇷Seoul, Korea, Republic of
University of Puerto Rico - Medical Science Campus; Internal Medicine
🇵🇷San Juan, Puerto Rico
FSBMEI HPE "Military Medical Academy n.a. S.M. Kirov" of the MoD of the RF
🇷🇺Sankt-peterburg, Sankt Petersburg, Russian Federation
Senior Adults Specialty Research
🇺🇸Austin, Texas, United States
National Clinical Research Inc.-Richmond
🇺🇸Richmond, Virginia, United States
Boston Center for Memory
🇺🇸Newton, Massachusetts, United States
Precise Research Centers
🇺🇸Flowood, Mississippi, United States
Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre
🇦🇺Heidelberg West, Victoria, Australia
Hospital Universitario Marques de Valdecilla; Servicio de Neurología
🇪🇸SANtander, Cantabria, Spain
Hospital San Pedro; Servicio de Neurología
🇪🇸Logroño, LA Rioja, Spain
Charing Cross Hospital
🇬🇧London, United Kingdom
Related News
Amyloid-Related Imaging Abnormalities in Clinical Trials of Gantenerumab in Early ...
- Prev
- 1
- Next